Raut Lalit S, Chakrabarti Prantar P
Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India.
South Asian J Cancer. 2014 Jan;3(1):66-70. doi: 10.4103/2278-330X.126531.
Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.
复发难治性弥漫性大B细胞淋巴瘤（RR DLBCL）约占DLBCL患者的三分之一，仍然是发病和死亡的主要原因。对血液肿瘤医生来说，治疗RR DLBCL仍然是一项挑战。挽救性大剂量化疗后进行自体干细胞移植是DLBCL化疗敏感复发的标准治疗方法。有多种挽救方案可供选择，但寻找最佳方案的工作仍在继续。在挽救方案中加入利妥昔单抗改善了RR DLBCL的治疗效果。本简短综述讨论了关于RR DLBCL治疗的几个相关问题。
